These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 12181044

  • 1. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 2. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
    Med Oncol; 2004 Sep; 21(4):349-58. PubMed ID: 15579919
    [Abstract] [Full Text] [Related]

  • 3. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 4. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
    Wang L, Pearson K, Ferguson JE, Clark RE.
    Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069
    [Abstract] [Full Text] [Related]

  • 5. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.
    Blood; 2003 Jun 15; 101(12):4701-7. PubMed ID: 12576334
    [Abstract] [Full Text] [Related]

  • 6. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep 15; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 15; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 11. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Rios MB, Shan J, Arlinghaus R.
    Clin Cancer Res; 2003 Jan 15; 9(1):160-6. PubMed ID: 12538464
    [Abstract] [Full Text] [Related]

  • 12. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
    Martinelli G, Iacobucci I, Rosti G, Pane F, Amabile M, Castagnetti F, Cilloni D, Soverini S, Testoni N, Specchia G, Merante S, Zaccaria A, Frassoni F, Saglio G, Baccarani M.
    Ann Oncol; 2006 Mar 15; 17(3):495-502. PubMed ID: 16403813
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
    Goldman J.
    Curr Opin Hematol; 2005 Jan 15; 12(1):33-9. PubMed ID: 15604889
    [Abstract] [Full Text] [Related]

  • 16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 Jan 15; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 17. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
    Morel F, Bris MJ, Herry A, Calvez GL, Marion V, Abgrall JF, Berthou C, Braekeleer MD.
    Eur J Haematol; 2003 Apr 15; 70(4):235-9. PubMed ID: 12656747
    [Abstract] [Full Text] [Related]

  • 18. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
    Ross DM, Branford S, Moore S, Hughes TP.
    Leukemia; 2006 Apr 15; 20(4):664-70. PubMed ID: 16482210
    [Abstract] [Full Text] [Related]

  • 19. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Sawyers CL.
    Semin Hematol; 2001 Jul 15; 38(3 Suppl 8):15-21. PubMed ID: 11526597
    [Abstract] [Full Text] [Related]

  • 20. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.
    Leukemia; 2002 Nov 15; 16(11):2190-6. PubMed ID: 12399961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.